{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-025509","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2023-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.837272+00:00","generated_at":"2026-06-10T22:04:23.181441+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vistagen enters exclusive negotiation with Fuji Pharma for PH80 in Japan; receives $1.5M upfront","bullets":["Fuji Pharma pays $1.5M non-refundable for up to ~18-month exclusive negotiation for PH80 license in Japan.","PH80 is a neuroactive nasal spray for acute treatment of moderate to severe menopausal hot flashes.","Exploratory Phase 2A showed statistically significant reduction in hot flash frequency and severity vs placebo.","If a definitive license agreement is signed, the $1.5M will be creditable against the signing fee.","Neither party is obligated to reach a definitive agreement; negotiations may terminate after exclusive period."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-025509","json":"https://secwatch.observer/filing/0001437749-23-025509.json","markdown":"https://secwatch.observer/filing/0001437749-23-025509.md","text":"https://secwatch.observer/filing/0001437749-23-025509.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923025509/0001437749-23-025509-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923025509/vtgn20230908_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:04:23.181441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2dd78bdc90667662697a0e43cd7aca39fbc40ce0","claim":"Vistagen Therapeutics, Inc. entered into Exclusive Negotiation Agreement with Fuji Pharma Co., Ltd. valued at $1,500,000 (effective 2023-09-01).","evidence_excerpt":"On September 1, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) entered into an Exclusive Negotiation Agreement (the “ Negotiation Agreement ”) by and among the Company and Fuji Pharma Co., Ltd.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000143774923025509/0001437749-23-025509-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Fuji Pharma Co., Ltd."},{"label":"Value","value":"$1,500,000"},{"label":"Effective","value":"2023-09-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}